In KBD, cartilage extracellular matrix (ECM) destruction and abnormal homeostasis are gaining increasing attention as therapeutic targets for cartilage regeneration. Moreover, during the progression of KBD, the cartilage ECM showed significant pathological changes, which may be a research-meaningful biomarkerfor identifying the pathological stage of KBD. In this review, we summarize the abnormal ECM, the role of homeostasis in articular cartilage during KBD, and the association of ECM with other relevantfactors. Furthermore, we provide the cartilage ECM-related factors and their interrelationships.

Zirong Zhou, Jiushe Kou. Exploration of the mechanism of MMPs for ECM in KBD cartilage. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 9: 69-77. https://doi.org/10.25236/AJMHS.2023.040911.

[1] Chen Jinghong, et al. Altered proteolytic activity and expression of MMPs and aggrecanases and their inhibitors in Kashin-Beck disease [J]. Journal of orthopaedic research: official publication of the Orthopaedic Research Society, 2015, 33(1): 47-55.

[2] Wang Sen, et al. Genome-wide study identifies the regulatory gene networks and signaling pathways from chondrocyte and peripheral blood monocyte of Kashin-Beck disease [J]. Genes to cells: devoted to molecular & cellular mechanisms, 2012, 17(8): 619-632. 

[3] Li Siyuan, et al. Proteoglycan metabolism, cell death and Kashin-Beck disease [J]. Glycoconjugate journal, 2012, 29(5-6): 241-248. 

[4] Cao J, et al. Articular cartilage metabolism in patients with Kashin-Beck Disease: an endemic osteoarthropathy in China [J]. Osteoarthritis and cartilage, 2008, 16(6): 680-688.

[5] Wang Shijie, et al. Chondrocyte apoptosis and expression of Bcl-2, Bax, Fas, and iNOS in articular cartilage in patients with Kashin-Beck disease [J]. The Journal of rheumatology, 2006, 33(3): 615-619.  

[6] Ma Weijuan, et al. Cytoskeleton remodeling and oxidative stress description in morphologic changes of chondrocyte in Kashin-Beck disease [J]. Ultrastructural pathology, 2014, 38(6): 406-412. 

[7] Song Jinsoo, et al. MicroRNA-488 regulates zinc transporter SLC39A8/ZIP8 during pathogenesis of osteoarthritis [J]. Journal of biomedical science, 2013, 20(5): 31. 

[8] Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP- 1, MMP- 13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors [J]. Arthritis Res, 2002, 4(3):157-164.  

[9] Gentili C, Cancedda R. Cartilage and bone extracellular matrix [J]. Current Pharmaceutical Design, 2009, 15(12):1334-1348. 

[10] Krzysztof Fink, Janusz Boratyński. The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis [J]. Postępy Higieny i Medycyny Doświadczalnej, 2012, 66(855199):609-628.

[11] Bogaczewicz J, Sysa-Jedrzejowska A, Woźniacka A. Role of matrix metalloproteinases in primary systemic vasculitis [J]. Pol Merkur Lekarski, 2008, 24(140):85-89. 

[12] Gross J, Lapiere C M. Collagenolytic activity in amphibian tissues: a tissue culture assay [J]. Proceedings of the National Academy of Sciences of the United States of America, 1962, 48: 1014-1022. 

[13] Ulrich Eckhard, Pitter F. Huesgen, Oliver Schilling, et al. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses [J]. Matrix Biology, 2016, 49:37-60. 

[14] Jaclyn A. Konopka, Malcolm R. DeBaun, Wenteh Chang, et al. The Intracellular Effect of Relaxin on Female Anterior Cruciate Ligament Cells [J]. The American Journal of Sports Medicine, 2016, 44(9): 2384-2392. 

[15] Benjamin D. Shogan, Natalia Belogortseva, Preston M. Luong, et al. Collagen degradation and MMP9 activation by Enterococcus faecalis contribute to intestinal anastomotic leak [J]. Science Translational Medicine, 2015, 7(286):286ra68-286ra68. 

[16] Andreini Claudia, Banci Lucia, Bertini Ivano, et al. Comparative analysis of the ADAM and ADAMTS families [J]. Journal of proteome research, 2005, 4(3):881-888. 

[17] Hrabec E, Naduk J, Strek M, Hrabec Z. Type IV collagenases (MMP-2 and MMP-9) and their substrates--intracellular proteins, hormones, cytokines, chemokines and their receptors [J]. Postepy Biochem, 2007, 53(1):37-45. 

[18] Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: versatile extracellular regulators in cancer [J]. Nat Rev Cancer, 2017, 17(1):38-53. 

[19] Gomis-Rüth F X, Maskos K, Betz M, et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1 [J]. Nature, 1997, 389(6646):77-81. 

[20] Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, DochertyAJ. The N- terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity [J]. Biochemistry, 1991, 30(33):8097- 8102. 

[21] Huang W, Suzuki K, Nagase H, Arumugam S, Van Doren SR, Brew K. Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield in E. coli [J]. Febs Letters, 1996, 384(2):155-161. 

[22] Raeeszadeh-Sarmazdeh M, Greene KA, Sankaran B, Downey GP, Radisky DC, Radisky ES. Directed evolution of the metalloproteinase inhibitor TIMP- 1 reveals that its Nand C-terminal domains cooperate in matrix metalloproteinase recognition [J]. Journal of Biological Chemistry, 2019, 294(24):9476-9488.

[23] Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity [J]. Biochim Biophys Acta, 2010, 1803(1):55-71.

[24] Jobin PG, Butler GS, Overall CM. New intracellular activities of matrix metalloproteinases shine in the moonlight [J]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(11 PtA):2043-2055. 

[25] Butler G S, Apte S S, Willenbrock F, et al. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions [J]. The Journal of biological chemistry, 1999, 274(16):10846-10851. 

[26] O'Connell J P, Willenbrock F, Docherty A J, et al. Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B [J]. The Journal of biological chemistry, 1994, 269(21):14967-14973. 

[27] Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity [J]. Biochim Biophys Acta, 2010, 1803(1):55-71. 

[28] Morgunova Ekaterina, Tuuttila Ari, Bergmann Ulrich, et al. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2 [J]. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99(11): 7414-7419. 

[29] Goldberg G I, Strongin A, Collier I E, et al. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin [J]. The Journal of biological chemistry, 1992, 267(7):4583-4591.

[30] Ogata Y, ItohY, Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases- 1 complex by 4-aminophenylmercuric acetate and proteinases [J]. Journal of Biological Chemistry, 1995, 270(31):18506-18511. 

[31] Ardi Veronica C, Kupriyanova Tatyana A, Deryugina Elena I, et al. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis [J]. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104(51):20262-20267. 

[32] Ardi VC, Van den Steen PE, Opdenakker G, Schweighofer B, Deryugina EI, Quigley JP. Neutrophil MMP-9 proenzyme, unencumbered by TIMP- 1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway [J]. Journal of Biological Chemistry, 2009, 284(38):25854-25866. 

[33] Wayne GJ, Deng SJ, Amour A, Borman S, Matico R, Carter HL, Murphy G. TIMP-3 inhibition of ADAMTS-4 (Aggrecanase- 1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4 [J]. Journal of Biological Chemistry, 2007, 282(29):20991-20998.

[34] Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5) [J]. Journal of Biological Chemistry, 2001, 276(16): 12501-12504. 

[35] Augustin Amour, C.Graham Knight, Ailsa Webster, et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3 [J]. FEBS Letters, 2000, 473(3):275-279. 

[36] Murphy G. Tissue inhibitors of metalloproteinases [J]. Genome Biol, 2011, 12(11):233.

[37] Rhee Jin-Sae, Diaz Robert, Korets Lidiya, et al. TIMP-1 alters susceptibility to carcinogenesis [J]. Cancer research, 2004, 64(3):952-961. 

[38] Liliana Guedez, Andrew J. McMarlin, Douglas W. Kingma, et al. Tissue Inhibitor of Metalloproteinase-1 Alters the Tumorigenicity of Burkitt’s Lymphoma via Divergent Effects on Tumor Growth and Angiogenesis [J]. The American Journal of Pathology, 2001, 158(4):1207-1215. 

[39] Cui H, Seubert B, Stahl E, et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes [J]. Oncogene, 2015, 34(28):3640-3650.